I thought the HSV mouse results were pretty spectacular as well. HSV was worth the moon shot because, unlike immuno-oncology, literally nobody of note was working on HSV. That was a big market opportunity for first movers. Immuno-oncology is such a crowded space and we are literally years behind the competition. Will be amazing if we score a deal in the next week or two because that will be awesome validation of the quality of our programs - in that a consortium is willing to take an equity position in candidates that are a few years behind competitors.
Under the Radar, page-177
-
- There are more pages in this discussion • 362 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.76 |
Change
-0.390(3.21%) |
Mkt cap ! $258.9M | |||
| Open | High | Low | Value | Volume |
| $12.15 | $12.27 | $11.27 | $382.7K | 32.38K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 420 | $11.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.85 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |